Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

Cancer Communications

Gioconda Saccoccio^{1  2}  Andrea Palloni²  Ingrid Garajovಠ Giovanni Brandi²  Stefania De Lorenzo²  Rita Golfieri²  Maria Abbondanza Pantaleo²  Michela Venturi²  Giorgio Frega²  Francesca Garuti³  Francesca Abbati⁴ 

[1] Department of Digestive Diseases and Internal Medicine, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;Department of Experimental, Diagnostic and Specialty Medicine, St. Orsola-Malpighi Hospital, Haematological and Oncological Institute, University of Bologna, Bologna, Italy;Department of Medical and Surgical Sciences, St. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy;Department of Medicine, Bologna Health Authority, Bologna, Italy

关键词: Hepatocellular carcinoma;    Capecitabine;    Metronomic capecitabine;    Complete response;    Sorafenib;   

DOI  :  10.1186/s40880-018-0312-1

学科分类：肿瘤学

来源: Springer

【 摘 要 】

Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to treatment is infrequently reported. Capecitabine, an oral fluoropyrimidine, has been shown to be effect in both treatment-naïve patients and those previously treated with sorafenib. To date, however, only one case of sustained CR to metronomic capecitabine has been reported. We describe three cases of advanced HCC treated with metronomic capecitabine where a CR was obtained. In the first case, capecitabine was administered as first line therapy; in the second case, capecitabine was used after intolerance to sorafenib; while in the third case, capecitabine was administered after sorafenib failure. Capecitabine is a potentially important treatment option for patients with advanced HCC and may even represent a cure in certain cases.

【 授权许可】

CC BY